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A b s t r a c t
Introduction: Cardiac resynchronization therapy (CRT) was a breakthrough in the treatment of heart failure, but data regarding 
the effect of this therapy on numerous disorders associated with heart failure are limited.
Aim: To assess the impact of CRT on sleep breathing disorders, and to determine the relationship between the changes in the 
autonomous nervous system and sleep disorders after CRT.
Material and methods: The study included 55 patients with chronic heart failure stable for at least last 3 months, in New York 
Heart Association (NYHA) class III or IV despite optimal medical therapy, with a reduced left ventricular ejection fraction (LVEF) 
≤ 35%, QRS complex duration ≥ 120 ms, and sinus rhythm. Before and 3 months after implementation of CRT echocardiography, 
6-minute walk test (6MWT), polysomnography with the Pittsburgh Sleep Quality Index (PSQI) questionnaire and the Epworth Sleep-
iness Scale (ESS) were performed. Also baroreflex sensitivity (BRS) was evaluated.
Results: After implementation of CRT, the values of the apnea-hypopnea index (AHI), apnea index (AI), and central and mixed 
apnea indexes (CAI, MAI) were statistically significantly reduced. The strongest negative correlations were demonstrated for chang-
es in CAI and changes in BRS. An improvement in sleep quality, daytime sleepiness, LVEF, NYHA class, and 6MWT was observed and 
was the most strongly associated with the improvement in CAI, too.
Conclusions: CRT has a beneficial effect on subjective and objective features of sleep, as well as on the function of the autono-
mous nervous system. In addition, patients with heart failure and coexisting central sleep apnea may benefit most from this therapy.
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S u m m a r y
The publication concerns the assessment of sleep breathing disorders as well as their interactions with the function 
of the autonomous nervous system after cardiac resynchronization therapy (CRT). After a 3-month observation period, the 
improvement in sleep breathing disorders, the quality of sleep, daytime sleepiness, clinical and echocardiographic parame-
ters accompanied the improvement in the baroreflex sensitivity (BRS). In addition, among the analyzed breathing disorders 
during sleep, the presence of the central type of sleep apnea was associated with the greatest benefits of using CRT.
Introduction
Heart failure is a major and constantly increasing health 
problem. Currently the condition affects at least 26 million 
people worldwide [1]. Patients with chronic heart failure 
commonly suffer from breathing disorders during sleep 
[2–4]. It is estimated that sleep apnea occurs in 47–76% of 
patients with heart failure [5]. Heart failure is the principal 
risk factor of sleep breathing disorders, which may create 
a vicious circle of negative effects on the cardiovascular sys-
tem [6]. The presence of breathing disorders during sleep in 
patients with heart failure is associated with increased risk 
of cardiovascular morbidity and mortality [7, 8]. 
Creative Commons licenses: This is an Open Access article distributed under the terms of the Creative Commons  
Attribution-NonCommercial-ShareAlike 4.0 International (CC BY -NC -SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/).
Anna Przybyła et al. Sleep disorders after CRT
358 Advances in Interventional Cardiology 2019; 15, 3 (57)
The development of cardiac resynchronization thera-
py (CRT), which improves the exercise capacity, reduces 
the frequency of hospitalization associated with exacer-
bation of heart failure, reduces mortality, and improves 
the quality of life, has been a breakthrough in the treat-
ment of heart failure [9–11]. The favorable effect of CRT 
on the prognosis and comfort of life may also be related 
to its impact on numerous disorders that accompany 
heart failure. 
Aim
The aim of the present study was to assess the im-
pact of CRT on sleep breathing disorders, and to deter-
mine the relationship between the changes observed in 
the autonomous nervous system and sleep disorders af-
ter the introduction of this therapy.
Material and methods 
The study covered a group of 55 patients with chron-
ic heart failure stable for at least the last 3 months, in 
New York Heart Association (NYHA) class III or IV despite 
optimal medical therapy, with a reduced left ventricular 
ejection fraction (LVEF) ≤ 35%, QRS complex duration 
≥ 120 ms, and sinus rhythm. Patients who did not agree 
to participate in the study, had atrial fibrillation/flutter, 
had a sinus node disease, second or third degree atrio-
ventricular block, implanted pacemaker, had numerous 
ventricular or supraventricular ectopic beats (more than 
5% of all QRS complexes recorded), were hospitalized 
due to unstable angina, myocardial infarction or heart 
failure in the period of 3 months before implantation of 
the cardiac resynchronization system, underwent cor-
onary artery bypass grafting or percutaneous coronary 
intervention within 3 months before implantation of 
the cardiac resynchronization system, underwent heart 
transplant surgery, had peripheral neuropathy, had con-
traindications for surgical procedures, who were treated 
for sleep disorders, and who participated in another re-
search program at the time of the start of the study were 
excluded. In the case of coherence between RR interval 
and systolic blood pressure less than 0.5, patients were 
excluded from the research, too. In addition, pregnant 
women and patients whose heart failure was secondary 
to reversible conditions were excluded from the study. 
The study was conducted according to the principles 
of the Helsinki Declaration, and it was approved by the 
Institutional Ethical Committee. All enrolled patients 
were informed about the course of the study, and written 
informed consent for participation in this study was then 
obtained. 
Before the cardiac resynchronization system was im-
planted and after 3 months of observation, each patient 
underwent an interview and physical examination, elec-
trocardiography at rest, echocardiography, 6-minute walk 
test (6MWT) and polysomnography with the Pittsburgh 
Sleep Quality Index (PSQI) questionnaire and the Ep-
worth Sleepiness Scale (ESS) completed by each subject. 
Also baroreflex sensitivity (BRS) was evaluated. An X-ray 
scan of the chest was performed before and 3 days after 
implementation of CRT. The PSQI questionnaire evaluat-
ed the following 7 sleep quality parameters: time needed 
to fall asleep, duration and effectiveness of sleep, sleep 
disorders, the use of sleeping pills, subjective sleep quali-
ty, and difficulties with daytime functioning. The result of 
each sleep quality parameter ranged from 0 to 3 points. 
The maximum score was 21. A result above 5 points indi-
cated poor quality of sleep [12]. Additionally, the ESS was 
used, which allowed the assessment of the probability 
of falling asleep in eight different situations occurring in 
everyday life. A response to each question was given ac-
cording to a 4-point scale (0–3), depending on the prob-
ability of falling asleep. The total score ranged between 
0 and 24. A total score higher than 10 points indicated 
subjective excessive daytime sleepiness [13–15]. The 
sleep examination was performed in a hospital setting, in 
a single room, at night, using the Embla S 4000 polysom-
nographic system. The Somnologica software was used 
for the analysis of obtained data. The polysomnographic 
examination involved: single-channel electrocardiogra-
phy, 3-channel electromyography, 2-channel electroocu-
lography, 6-channel electroencephalography, and regis-
tration of the sound of snoring and air-flow through the 
nose/mouth. The patient’s body position, movements of 
the chest and abdomen, as well as pulse oximetry were 
also monitored. Apnea was defined as an episode lasting 
for at least 10 s of a reduction in air-flow amplitude by 
≥ 90% of the pre-event baseline. Apnea episodes were 
divided into: obstructive, central, and of mixed back-
ground. The classification was based on the recorded ac-
tivity of respiratory muscles. Obstructive sleep apnea was 
diagnosed when an episode of a  reduction in air-flow 
amplitude by ≥ 90% of pre-event baseline lasting for at 
least 10 s was accompanied by respiratory movements 
of the chest and abdomen. Central sleep apnea was diag-
nosed in the case of an episode of a reduction in air-flow 
amplitude by ≥ 90% of the pre-event baseline lasting 
for at least 10 s with no respiratory movements of the 
chest and abdomen. Mixed sleep apnea was defined as 
a combination of central sleep apnea at the initial phase 
and obstructive sleep apnea in the final phase. Hypopnea 
was defined as a reduction of the amplitude of air-flow 
by at least 30% of the pre-event baseline lasting for at 
least 10 s, accompanied by oxygen desaturation by ≥ 3% 
from the pre-event baseline or arousal [16]. The following 
polysomnographic parameters were analyzed: apnea-hy-
popnea index (AHI) indicating the number of apnea and 
hypopnea episodes per hour of sleep, apnea index (AI) 
corresponding to the number of apnea episodes per hour 
of sleep, obstructive apnea index (OAI) indicating the 
number of obstructive apnea episodes per hour of sleep, 
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central apnea index (CAI) indicating the number of cen-
tral apnea episodes per hour of sleep, mixed apnea index 
(MAI) indicating the number of mixed apnea episodes per 
hour of sleep, hypopnea index (HI) indicating the number 
of hypopnea episodes per hour of sleep. The examination 
of BRS was carried out in a quiet room, after a 15-minute 
rest in a lying position, for stabilization of the cardiovas-
cular system. All subjects refrained from eating, drinking 
coffee and smoking for 3 h before the start of the exam-
ination. The protocol involved registration of signals in 
a lying position with spontaneous respiration for 10 min. 
Arterial blood pressure was monitored using the beat-to-
beat method (Finometer Pro device – Finapres Medical 
Systems B.V.). An electrocardiogram was recorded, too. 
Baroreflex sensitivity was evaluated with non-invasive 
methods: spectral analysis and the sequence method 
(BRSseq). The α coefficient for the LF component (spec-
tral power at low frequencies ranging between 0.04 and 
0.14 Hz) and for the HF component (spectral power at 
high frequencies ranging between 0.15 and 0.4 Hz) was 
calculated as the square root of the quotient of the spec-
tral power variability of the RR interval and systolic blood 
pressure. The transfer function modulus (TF) was calcu-
lated between RR interval oscillations and oscillations of 
systolic blood pressure for the LF and HF components. 
Assessment of baroreflex sensitivity using the sequen-
tial technique was based on the automatic capture of 
sequences of four or more consecutive heart evolutions, 
where the increase or decrease in systolic blood pressure 
was accompanied by a  corresponding gradual increase 
or decrease of the length of the heart cycle. The slope of 
the regression curve plotted for the correlation between 
changes in systolic blood pressure and changes in the RR 
interval was assumed as the value of BRSseq [17]. 
Statistical analysis
The statistical analysis was performed using the 
Statistica 10 software and was presented as mean val-
ue ± standard deviation (SD), median with interquartile 
range (Q1–Q3) or percentages. Parameters were tested 
for normal distribution with the Shapiro-Wilk test. Data 
were analyzed using the Wilcoxon signed-rank test, the 
Mann-Whitney U  test and Spearman’s rank correlation 
coefficient. A p-value of < 0.05 was considered statisti-
cally significant.
Results
Fifty-five patients were enrolled in the study, includ-
ing 45 males (81.8% of subjects) and 10 females (18.2% 
of subjects). The clinical characteristic and pharmaco-
therapy of the study population are presented in Table I. 
After a  3-month observation period, the QRS com-
plexes narrowed (170 (160–200) vs. 140 (120–160) ms, 
p < 0.001) and also the echocardiography showed a sig-
nificant improvement in LVEF (26% (21–32%) vs. 32% 
(27–37%), p < 0.001). In addition, the severity of heart 
failure assessed according to the NYHA classification 
significantly decreased (3.11 ±0.31 vs. 2.2 ±0.58, p < 
0.001) and the distance covered by the patients during 
the 6-minute walk test increased (300 (250–320) vs. 360 
(300–400) m, p < 0.001).
In the study group, at baseline, 43.6% of patients had 
apnea that was predominantly central, 38.2% of patients 
had apnea that was predominantly obstructive and 18.2% 
of patients had apnea that was predominantly mixed. 
Polysomnography indicated a significant reduction in AHI 
after 3 months from CRT implementation. There was also 
a significant reduction in AI, CAI, and MAI. There were no 
significant changes in OAI or in HI. The evaluated poly-
Table I. Clinical characteristics and pharmacothe-
rapy of the study group (n = 55)
Parameter Results
Male gender 81.8
Age [years] 67.04 ±9.13
Body mass index [kg/m²] 27.87 ±4.81
Ischemic heart disease 70.9
Dilated cardiomyopathy 29.1
History of myocardial infarction 61.8
History of percutaneous coronary intervention 36.4
History of coronary artery bypass grafting 16.4




History of stroke 7.3











Data presented as mean value ± standard deviation (SD) or percentage of 
patients (%). ACEI – angiotensin-converting enzyme inhibitor, ARB – angioten-
sin receptor blocker, ASA – acetylsalicylic acid, MRA – mineralocorticoid receptor 
antagonist.
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somnographic parameters are presented in Table II. An 
improvement defined as 50% or more reduction in the 
number of obstructive sleep apnea episodes was reported 
in 23.8% of patients with this type of sleep breathing dis-
orders. There were no statistically significant differences in 
baseline LVEF (p = 0.364), NYHA class (p = 0.283), 6MWT 
(p = 0.409), or body mass index (BMI) (p = 0.433) between 
groups of patients with obstructive sleep apnea respond-
ing and not responding to cardiac resynchronization ther-
apy according to the accepted improvement criterion. In 
the examined group of patients, before the use of CRT, the 
subjects with AHI exceeding 30 events per hour of sleep 
prevailed. After the cardiac resynchronization system was 
implanted, the dominant group consisted of patients with 
AHI of 15–30 events per hour of sleep. Moreover, intro-
duction of CRT resulted in significant improvement of the 
quality of sleep assessed with the PSQI questionnaire, and 
also in significant reduction of daytime sleepiness as mea-
sured with the ESS (Table III).
In the analysis of interrelations between the assessed 
parameters, statistically significant negative correlations 
between changes in AHI, AI, CAI and changes in BRS 
evaluated with all three methods in the supine position 
during spontaneous breathing were demonstrated. Also 
the relationships between changes in MAI and changes 
in BRSseq, α HF and TF HF were statistically significant. 
Among the analyzed types of sleep breathing disorders, 
the strongest negative correlations were observed be-
tween changes in CAI and changes in BRS evaluated with 
all three methods. Significant negative correlations were 
observed between changes in intensity of daytime sleep-
iness and changes in BRS. In addition, significant nega-
tive correlations between changes in sleep quality and 
changes in the values of BRSseq, α HF, and TF HF were 
noted in the study group. However, no significant correla-
tions were found between changes in sleep quality and 
changes in α LF and TF LF values. Statistically significant 
positive correlations were observed between changes in 
LVEF, 6MWT and changes in BRSseq, α HF, TF HF. There 
were significant negative correlations between chang-
es in NYHA class and changes in BRSseq, α HF, TF HF. 
Non-significant correlations were noted between chang-
es in LVEF, NYHA class, 6MWT and changes in α LF, TF LF. 
The results mentioned above are presented in Table IV. 
The mutual associations between changes in poly-
somnographic parameters and changes in the quality of 
sleep, daytime sleepiness, LVEF, NYHA class, 6MWT oc-
curring after 3 months of CRT are presented in Table V. It 
was observed that changes in AHI, AI and CAI were sig-
nificantly correlated with changes in the quality of sleep, 
daytime sleepiness and changes in LVEF, NYHA class, and 
6MWT. Moreover, there was a statistically significant pos-
itive correlation between changes in MAI and changes 
in the subjective assessment of sleep quality. However, 
there were no significant correlations between changes 
in OAI, MAI, HI and changes in LVEF, NYHA class, 6MWT, 
as well as between changes in OAI, HI and changes in the 
quality of sleep, and also between changes in OAI, MAI, 
HI and changes in daytime sleepiness.
There were statistically significant negative correla-
tions between changes in the quality of sleep and changes 
in LVEF and 6MWT, as well as a statistically significant pos-
itive correlation between changes in the quality of sleep 
and changes in NYHA class. Also, changes in the severity of 
daytime sleepiness correlated negatively, significantly with 
changes in LVEF. The results are shown in Table VI.
Discussion
In the present study, the values of AHI, AI, CAI, and 
MAI were significantly reduced after 3 months of CRT. 
Table II. Polysomnographic parameters evaluated before and 3 months after implementation of cardiac resyn-
chronization therapy
Parameter Baseline Follow-up P-value
AHI [events/h] 33.4 (19.2–44.5) 23.4 (8.5–33.25) < 0.001
AI [events/h] 23.22 (11.1–31.31) 12.77 (2.89–21) < 0.001
OAI [events/h] 3.89 (2.04–10.97) 3.43 (1.22–9.41) 0.067
CAI [events/h] 6.01 (1.52–11.92) 0.45 (0–4.31) < 0.001
MAI [events/h] 4.4 (1.24–9.66) 2.99 (0.27–9.4) 0.009
HI [events/h] 8.12 (4.35–14.2) 7.03 (2.85–15.03) 0.11
Data presented as median (Q1–Q3). AHI – apnea-hypopnea index, AI – apnea index, CAI – central apnea index, HI – hypopnea index, MAI – mixed apnea index, 
OAI – obstructive apnea index.
Table III. Sleep quality and daytime sleepiness be-
fore and 3 months after implantation of the car-
diac resynchronization system
Parameter Baseline Follow-up P-value
PSQI 11 (8–13) 5 (3–7) < 0.001
ESS 11 (7–13) 7 (4–10) < 0.001
Data presented as median (Q1–Q3). ESS – Epworth Sleepiness Scale, PSQI – 
Pittsburgh Sleep Quality Index.
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Table V. Correlations between changes in the objective sleep parameters and changes in the subjective sleep 
parameters, left ventricular ejection fraction, NYHA class, 6-minute walk test
Parameter ∆ ESS ∆ PSQI ∆ LVEF (%) ∆ NYHA class ∆ 6MWT [m]
r P-value r P-value r P-value r P-value r P-value
∆ AHI [events/h] 0.443 < 0.001 0.528 < 0.001 –0.517 < 0.001 0.38 0.004 –0.513 < 0.001
∆ AI [events/h] 0.413 0.002 0.533 < 0.001 –0.553 < 0.001 0.378 0.004 –0.508 < 0.001
∆ OAI [events/h] 0.172 0.208 0.235 0.084 –0.139 0.31 0.195 0.154 –0.134 0.329
∆ CAI [events/h] 0.437 < 0.001 0.373 0.005 –0.524 < 0.001 0.372 0.005 –0.57 < 0.001
∆ MAI [events/h] 0.257 0.058 0.276 0.042 –0.213 0.119 0.202 0.14 –0.101 0.465
∆ HI [events/h] 0.198 0.148 0.143 0.297 –0.128 0.353 0.189 0.166 –0.22 0.106
AHI – apnea-hypopnea index, AI – apnea index, CAI – central apnea index, ESS – Epworth Sleepiness Scale, HI – hypopnea index, LVEF – left ventricular ejection 
fraction, MAI – mixed apnea index, NYHA – New York Heart Association, OAI – obstructive apnea index, PSQI – Pittsburgh Sleep Quality Index, 6MWT – 6-minute 
walk test.
Table IV. Correlations between changes in baroreflex sensitivity measured by the sequence method, the α co-
efficient, the transfer function modulus and changes in the polysomnographic parameters, daytime sleepiness, 
sleep quality, left ventricular ejection fraction, NYHA class, 6-minute walk test
Parameter ∆ BRSseq [ms/mm Hg] ∆ α LF [ms/mm Hg] ∆ α HF [ms/mm Hg] ∆ TF LF [ms/mm Hg] ∆ TF HF [ms/mm Hg]
r P-value r P-value r P-value r P-value r P-value
∆ AHI [events/h] –0.442 < 0.001 –0.304 0.024 –0.518 < 0.001 –0.299 0.027 –0.524 < 0.001
∆ AI [events/h] –0.485 < 0.001 –0.331 0.014 –0.523 < 0.001 –0.392 0.003 –0.521 < 0.001
∆ OAI [events/h] –0.257 0.058 –0.091 0.509 –0.164 0.233 –0.154 0.261 –0.197 0.149
∆ CAI [events/h] –0.385 0.004 –0.277 0.04 –0.469 < 0.001 –0.333 0.013 –0.482 < 0.001
∆ MAI [events/h] –0.374 0.005 –0.193 0.158 –0.296 0.028 –0.236 0.083 –0.328 0.014
∆ HI [events/h] –0.084 0.541 –0.061 0.659 –0.101 0.465 –0.021 0.881 –0.168 0.221
∆ ESS –0.368 0.006 –0.321 0.017 –0.435 < 0.001 –0.315 0.019 –0.445 < 0.001
∆ PSQI –0.338 0.012 –0.213 0.118 –0.342 0.011 –0.18 0.189 –0.349 0.009
∆ LVEF [%] 0.505 < 0.001 0.246 0.07 0.413 0.002 0.176 0.198 0.368 0.006
∆ NYHA class –0.304 0.024 –0.152 0.267 –0.44 < 0.001 –0.212 0.12 –0.432 < 0.001
∆ 6MWT [m] 0.288 0.033 0.205 0.134 0.424 0.001 0.197 0.15 0.479 < 0.001
AHI – apnea-hypopnea index, AI – apnea index, α HF – α coefficient in the high frequency band, α LF – α coefficient in the low frequency band, BRSseq – baroreflex 
sensitivity measured by the sequence method, CAI – central apnea index, ESS – Epworth Sleepiness Scale, HI – hypopnea index, LVEF – left ventricular ejection frac-
tion, MAI – mixed apnea index, NYHA – New York Heart Association, OAI – obstructive apnea index, PSQI – Pittsburgh Sleep Quality Index, 6MWT – 6-minute walk 
test, TF HF – transfer function modulus in the high frequency band, TF LF – transfer function modulus in the low frequency band.
Table VI. Correlations between changes in clinical and echocardiographic parameters and changes in subjec-
tive sleep parameters
Parameter ∆ LVEF (%) ∆ NYHA class ∆ 6MWT [m]
r P-value r P-value r P-value
∆ PSQI –0.512 < 0.001 0.305 0.023 –0.53 < 0.001
∆ ESS –0.342 0.011 0.259 0.056 –0.209 0.126
ESS – Epworth Sleepiness Scale, LVEF – left ventricular ejection fraction, NYHA – New York Heart Association, PSQI – Pittsburgh Sleep Quality Index, 6MWT – 6-min-
ute walk test.
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Moreover, no significant changes in OAI and HI were not-
ed. In the literature there are controversial data about 
the influence of CRT on sleep breathing disorders. Lüth-
je et al. demonstrated that CRT significantly reduces the 
central apnea-hypopnea index remaining without a sig-
nificant impact on the obstructive apnea-hypopnea index 
[18]. By contrast, Stanchina et al. assessing the effect 
of CRT on obstructive respiratory events observed a de-
crease in AHI [19]. In addition, in the present study a sta-
tistically significant reduction in the number of episodes 
of central sleep apnea accompanied the improvement of 
LVEF. Significant negative correlations between changes 
in LVEF and changes in CAI, as well as between changes 
in LVEF and changes in AHI and AI, were noted. However, 
there were no statistically significant relationships be-
tween changes in LVEF and changes in OAI, MAI, or HI. 
This suggests the existence of a  relationship between 
the number of central sleep apnea episodes and the se-
verity of heart failure. 
The dysfunction of the autonomous nervous system 
may be manifested by a decrease in baroreflex sensitiv-
ity [20]. In the present study, negative correlations be-
tween changes in baroreflex sensitivity and changes in 
the polysomnographic parameters were demonstrated. 
Statistically significant negative correlations were found 
between changes in AHI, AI and changes in baroreflex 
sensitivity evaluated using the sequence method, the α 
coefficient and the transfer function modulus. Among the 
analyzed types of sleep breathing disorders, the stron-
gest correlations were demonstrated between changes 
in BRS and changes in CAI. The present results suggest 
that the improvement of sleep breathing disorders occur-
ring 3 months after the implementation of CRT is parallel 
to the improvement of baroreflex sensitivity. Assessment 
of baroreflex sensitivity may therefore play an important 
role in predicting the severity of sleep breathing disor-
ders. The significant reduction in the central apnea index 
with the strongest, among the analyzed types of sleep 
breathing disorders, statistically significant negative cor-
relations between the changes in this index and changes 
in baroreflex sensitivity may indicate that the patients 
with heart failure and the central type of sleep apnea will 
benefit most from implantation of the cardiac resynchro-
nization system. 
An important problem in patients with heart failure 
is the poor quality of sleep, which is a barrier to self-care 
and compliance with treatment in this group of patients 
[21]. In the present study, the improvement of the poly-
somnographic parameters was accompanied by an im-
provement in the subjective quality of sleep assessed 
using the PSQI questionnaire. Statistically significant cor-
relations between changes in sleep quality and changes 
in AHI, AI, and CAI were noted. A statistically significant, 
though weaker, correlation was observed between chang-
es in the quality of sleep and changes in MAI. In addition 
to assessing the quality of sleep, the subjective assess-
ment of daytime sleepiness is also an important element 
in the diagnosis of sleep disorders. Daytime sleepiness 
measured with the ESS was significantly decreased fol-
lowing CRT. An association between daytime sleepiness 
and baroreflex sensitivity was demonstrated in the pres-
ent study. It was found that the reduction of daytime 
sleepiness after the use of CRT was simultaneously asso-
ciated with increased baroreflex sensitivity. Statistically 
significant negative correlations were observed between 
changes in daytime sleepiness and changes in barore-
flex sensitivity measured using the sequence method, 
the α coefficient and the transfer function modulus. Oc-
currence of excessive daytime sleepiness may indicate 
changes in autonomous regulation of the heart work in 
patients with sleep breathing disorders. The reduction 
of AHI and daytime sleepiness coexisting with the in-
crease in BRS observed after the use of CRT indicates an 
increase in the activity of the parasympathetic part of 
the autonomous nervous system. Moreover, the obtained 
results suggest that an assessment of baroreflex sensi-
tivity and the apnea-hypopnea index may be useful in 
predicting the occurrence of daytime sleepiness and its 
severity. It is worth noting that after the implementation 
of cardiac resynchronization therapy, the improvement of 
clinical and echocardiographic parameters was accompa-
nied by an improvement in subjective sleep assessment, 
which intensified the benefits of this therapy.
The obtained results indicate that the use of cardiac 
resynchronization therapy may bring the greatest ben-
efits in patients with heart failure and the coexisting 
central type of sleep apnea. Already after a 3-month ob-
servation period, the implementation of cardiac resyn-
chronization therapy resulted in a significant reduction in 
the number of central sleep apnea episodes with simulta-
neous improvement in both clinical and echocardiograph-
ic parameters, subjective sleep parameters, as well as in 
the autonomous nervous system function. This suggests 
that the coexistence of central sleep apnea in patients 
with heart failure is a  predictor of response to cardiac 
resynchronization therapy. Therefore, screening for sleep 
breathing disorders prior to implantation of a cardiac re-
synchronization system may help identify patients with 
heart failure who will respond to cardiac resynchroniza-
tion therapy and will receive the greatest multidirectional 
benefits of this therapy. In addition, baroreflex sensitivity 
is a  reflection of the clinical and echocardiographic re-
sponse to CRT, as well as the severity of breathing disor-
ders during sleep, sleep quality and daytime sleepiness, 
so it can be used to assess the effectiveness of cardiac 
resynchronization therapy.
Conclusions
The present study showed that the use of CRT re-
duced the number of apnea-hypopnea episodes, and 
Anna Przybyła et al. Sleep disorders after CRT
363Advances in Interventional Cardiology 2019; 15, 3 (57)
in particular the number of central and mixed type 
sleep apnea episodes. Moreover, a  beneficial effect of 
CRT not only on objective but also subjective sleep fea-
tures, such as sleep quality and daytime sleepiness, was 
observed already after 3 months of this therapy. The 
improvement in sleep breathing disorders, the quality 
of sleep, daytime sleepiness, clinical and echocardio-
graphic parameters occurring after the implementation 
of CRT was associated with the improvement of the 
autonomous nervous system function. Due to a signif-
icant reduction of CAI after the use of CRT, and the oc-
currence of the strongest among the analyzed types of 
sleep breathing disorders, statistically significant nega-
tive correlations between changes in CAI and changes 
in BRS, and also because of the strongest relationship 
between improvement in CAI and improvement in sleep 
quality, daytime sleepiness, clinical and echocardio-
graphic parameters, it may be assumed that patients 
with heart failure and the central type of sleep apnea 
will benefit most from CRT. 
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